A recent second phase of a clinical trial of a recombinant IL-1R antagonist for multiple myeloma has shown a favorable safety profile and reduced morbidity, demonstrating that anti-IL-1 therapy is a viable cancer treatment option [106]. This evidence concerns the gene IL1A and AL amyloidosis.